Do risk factors for lactic acidosis influence dosing of metformin?

被引:10
作者
Millican, S
Cottrell, N
Green, B
机构
[1] Univ Queensland, Sch Pharm, Brisbane, Qld 4072, Australia
[2] Royal Brisbane & Womens Hosp, Dept Pharm, Brisbane, Qld, Australia
关键词
dose adjustment; lactic acidosis; metformin; prescribing practices; risk factors;
D O I
10.1111/j.1365-2710.2004.00589.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Metformin is commonly prescribed to treat type 2 diabetes mellitus, however it is associated with the potentially lethal condition of lactic acidosis. Prescribing guidelines have been developed to minimize the risk of lactic acidosis development, although some suggest they are inappropriate and have created confusion amongst prescribers. The aim of this study was to investigate whether metformin dose was influenced by the presence of risk factors for lactic acidosis. Methods: The study was prospective, and retrieved information from patients admitted to hospital who were prescribed metformin at their time of admission. Results: Eighty-three patients were included in the study, 60 of whom had a least one risk factor for lactic acidosis. Of those 60 patients, 78.3% had a dose adjustment, with renal impairment, hepatic impairment, surgery and use of radiological contrast media - the risk factors most likely to result in a dose adjustment. When dose adjustments did occur, metformin was withheld on 88.7% of occasions. Conclusion: Metformin dose was influenced by the presence of risk factors for lactic acidosis, although it was dependent upon the number and particular risk factor/s present.
引用
收藏
页码:449 / 454
页数:6
相关论文
共 29 条
  • [1] *ADRAC, 2001, ADVERSE DRUG REACT, V20, P2
  • [2] Drug therapy - Metformin
    Bailey, CJ
    Turner, RC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (09) : 574 - 579
  • [3] Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus
    Bytzer, P
    Talley, NJ
    Jones, MP
    Horowitz, M
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (01) : 137 - 142
  • [4] Evaluation of prescribing practices - Risk of lactic acidosis with metformin therapy
    Calabrese, AT
    Coley, KC
    DaPos, SV
    Swanson, D
    Rao, RH
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (04) : 434 - 437
  • [5] Metformin-associated lactic acidosis: a rare or very rare clinical entity?
    Chan, NN
    Brain, HPS
    Feher, MD
    [J]. DIABETIC MEDICINE, 1999, 16 (04) : 273 - 281
  • [6] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE
    COCKCROFT, DW
    GAULT, MH
    [J]. NEPHRON, 1976, 16 (01) : 31 - 41
  • [7] The relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: The Fremantle Diabetes Study
    Davis, TME
    Jackson, D
    Davis, WA
    Bruce, DG
    Chubb, P
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (02) : 137 - 144
  • [8] METFORMIN - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC USE IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS
    DUNN, CJ
    PETERS, DH
    [J]. DRUGS, 1995, 49 (05) : 721 - 749
  • [9] Contraindications to metformin therapy in patients with Type 2 diabetes - a population-based study of adherence to prescribing guidelines
    Emslie-Smith, AM
    Boyle, DIR
    Evans, JMM
    Sullivan, F
    Morris, AD
    [J]. DIABETIC MEDICINE, 2001, 18 (06) : 483 - 488
  • [10] *HIC PROF STAT, 2003, REP 1801T 2403X METF